Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

58
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
58
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

43
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
43
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.4K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.4K
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.9K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.9K
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

34
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
34
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

271
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
271

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Reply to letter to editor "Knowledge gaps in diabetic striatopathy and other movement disorders in diabetes".

Journal of endocrinological investigation·2023
Same author

Diabetic striatopathy: an updated overview of current knowledge and future perspectives.

Journal of endocrinological investigation·2023
Same author

Alpha1-antitrypsin deficiency in Greece: Focus on rare variants.

Pulmonology·2023
Same author

Rheumatological evaluation of patients with interstitial lung disease.

Scandinavian journal of rheumatology·2021
Same author

COVID-19 infection in severe Alpha 1-antitrypsin deficiency: Looking for a rationale.

Respiratory medicine·2021

Related Experiment Video

Updated: Nov 1, 2025

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.4K

[Compliance with biologic agents: Current situation].

S Ottaviani1, M Forien1

  • 1Service de rhumatologie, hôpital Bichat-Claude Bernard, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France.

Revue Des Maladies Respiratoires
|June 18, 2021
PubMed
Summary
This summary is machine-generated.

Patient education improves adherence and compliance with biologic agents for chronic inflammatory disorders. Understanding treatment and disease enhances patient knowledge, leading to better health outcomes.

Keywords:
AdherenceAdhésionBiologic agentsBiothérapieComplianceEducationÉducation

More Related Videos

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.0K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.9K

Related Experiment Videos

Last Updated: Nov 1, 2025

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.4K
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.0K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.9K

Area of Science:

  • Immunology
  • Pharmacology
  • Patient Adherence Research

Background:

  • Biologic agents improve chronic inflammatory disorder prognosis but face compliance challenges.
  • Patient compliance, the measurable follow-up of prescriptions, differs from adherence, the patient's acceptance of treatment.
  • Biologic agents generally show higher compliance rates than conventional therapies.

Purpose of the Study:

  • To explore factors influencing patient compliance and adherence to biologic therapies.
  • To evaluate the role of patient education in improving treatment adherence and compliance.

Main Methods:

  • Literature review on compliance and adherence factors in biologic therapy.
  • Analysis of patient-related factors and the patient-physician relationship's impact.
  • Examination of educational interventions for enhancing patient knowledge.

Main Results:

  • Treatment efficacy, patient factors, and the patient-physician relationship significantly influence compliance.
  • Improved compliance correlates with enhanced adherence.
  • Patient education programs effectively identify and address poor adherence.

Conclusions:

  • Patient education is a key strategy to improve adherence and compliance with biologic agents.
  • Enhanced patient knowledge of disease and treatment leads to better therapeutic outcomes.
  • Targeted educational measures can optimize the use of biologic therapies for chronic inflammatory conditions.